Zydus receives positive USFDA report for Ahmedabad facility

Zydus Lifesciences Limited has received an Establishment Inspection Report (EIR) for its SEZ – II manufacturing facility in Ahmedabad. This follows a USFDA inspection conducted from August 11th to 14th, 2025, which was categorized as a Pre-Approval Inspection (PAI) and concluded with no observations.

The USFDA has classified the facility as "No Action Indicated" (NAI), indicating a positive assessment of the plant's compliance. This announcement was made on November 5, 2025, and is considered a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.